employee
Russian Federation
UDC 61
Neuroendocrine tumors (NET) are among the relatively rare neoplasms and represent a heterogeneous group of malignant neoplasms with diverse morphology. Cases of NET in various organs have been described: the central nervous system, respiratory tract, larynx, gastrointestinal tract, thyroid gland, skin, mammary gland, and genitourinary system. According to various authors, NET accounts for about 0.5% of all newly diagnosed malignancies. In clinical practice, there is an increase in the frequency of NET detection, significant difficulties in their early recognition and treatment. CT scans, endoscopic examination, scintigraphy, positron emission tomography, and the study of biochemical markers are used to diagnose NET. The identification of the carcinoid syndrome accompanying NET is informative. The presence of carcinoid syndrome resulting from hypersecretion of amines and peptides often facilitates the diagnosis of NET. Surgical treatment remains the main method of treating localized forms of NET. Somatostatin analogues, interferon alpha, targeted drugs, and chemotherapy are used as standards for the drug treatment of NET.
neuroendocrine tumor, classification, diagnosis, treatment.
1. Gorbunova V.A., Orel N.F., Kuz'minov A.E. Sovremennye napravleniya lecheniya neyroendokrinnyh opuholey //Sovremennaya onkologiya. 2010. T. 1. S. 30-5.
2. Kvachenyuk A.N., Kvachenyuk D.A. Neyroendokrinnye opuholi: aspekty diagnostiki (obzor literatury) //Mezhdunarodnyy endokrinologicheskiy zhurnal. 2020. T. 16, № 1. S. 44-49.
3. Klinicheskie rekomendacii obscheros. nac. soyuza "Associaciya onkologov Rossii", obscheros. obsch. organizacii "Rossiyskoe obschestvo klin. onkologii", obsch. organizacii "Rossiyskaya Associaciya Endokrinologov". Neyroendokrinnye opuholi. M.: 2024. 52 s.
4. Neyroendokrinnye opuholi. Obschie principy diagnostiki i lecheniya. Prakticheskoe ruk-vo pod red. prof. V.A. Gorbunovoy. M.: GEOTAR-Media. 2021. 600 s.
5. Nosov N. A. i dr. Rol' PET/KT s 68 Ga-DOTATATE v dinamicheskom nablyudenii pacientov s neyroendokrinnymi opuholyami podzheludochnoy zhelezy: retrospektivnoe issledovanie //Onkologicheskiy zhurnal: luchevaya diagnostika, luchevaya terapiya. 2023. T. 6. №. 2. S. 9-19.
6. Pinskiy S.B., Beloborodov V.A., Batoroev Yu.K. i dr. Terminologiya i klassifikaciya neyroendokrinnyh opuholey //Novosti klinicheskoy citologii Rossii. 2015. T. 19, № 3-4. S. 15-22.
7. Tayurskaya V.E., Aleksanyan Yu.H. Diagnosticheskie vozmozhnosti komp'yuternoy tomografii pri opredelenii dal'neyshey taktiki vedeniya pacientov s verificirovannoy opuhol'yu podzheludochnoy zhelezy //Innovacionnaya medicina Kubani. 2024. № 4-1. S. 26.
8. Aunis D., Metz-Boutigue M.H. Chromogranins: current concepts. Structural and functional aspects // Adv. Exp. Med Biol. 2000. Vol.482. R. 21-38
9. Bevere M., Masetto F., Carazzolo M.E. et al. An overview of circulating biomarkers in neuroendocrine neoplasms: a clinical guide //Diagnostics. 2023. Vol. 13, № 17. P. 2820.
10. Eriksson B.G., Krenning E., Ahlman H. U. et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors-welldifferentiated jejuna-ileal tumor/carcinoma. Neuroendocrinology. 2008. Vol. 87. P. 8-19.
11. Esfahani S.A., Ferreira C.D.A., Summer P. et al. Addition of peptide receptor radiotherapy to immune checkpoint inhibition therapy improves outcomes in neuroendocrine tumors //Journal of nuclear medicine. 2023. Vol. 64, № 7. P. 1056-1061.
12. Gheorghișan-Gălățeanu A.A., Ilieșiu A., Lambrescu I.M., et al. The complex histopathological and immunohistochemical spectrum of neuroendocrine tumors – An overview of the latest classifications //International journal of molecular sciences. 2023. Vol. 24, № 2. P. 1418.
13. Helderman N.C., Suerink M., Kilinç G. et al. Relation between WHO classification and location-and functionality-based classifications of neuroendocrine neoplasms of the digestive tract //Neuroendocrinology. 2024. Vol. 114, № 2. P. 120-133.
14. La Salvia A., Modica R., Rossi R.E. et al. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists //Cancer treatment reviews. 2023. P. 102560.
15. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours //Endocr. Relat. Cancer. 2011. Vol.18, №1. R.17-25.
16. Prétot D., Engel-Bicik I., Kenkel D. et al. Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE //Journal of gastrointestinal oncology. 2023. Vol. 14, № 3. P. 1204.
17. Villa C., Baussart B., Assié G. et al. The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal //Endocrine-related cancer. 2023. Vol. 30, № 8. e230021.
